BIND Therapeutics appoints Andrew Hirsch as president and chief executive

Clinical-stage nanomedicines company BIND Therapeutics (Nasdaq: BIND) has appointed Andrew Hirsch as president and chief executive.

Mr Hirsch has been serving in the role on an acting basis since March, and he has also been elected to the BIND board of directors.

Daniel Lynch, chairman of the board, said: “After a thorough evaluation of internal and external candidates, the board is confident that Andrew is the right person to lead the next phase of the company’s growth. His vision, operational philosophy and experience are ideally suited for the position. Since stepping in as acting president and chief executive in March, we have been very impressed with his ability to quickly develop, and begin implementing, a strategic plan to drive current and future therapeutic opportunities in a direction we believe will most effectively create products that solve serious medical problems and create value for our shareholders.”